Ustekinumab – Treatment for Plaque Psoriasis
Key Data:
Drug (Brand/Generic)
Ustekinumab (CNTO 1275)
Company/Licensee
Centocor and Janssen-Cilag
Therapy Class
MAb
Product Description
Human anti-IL-12 and anti-IL-23 MAb
Current Indication
Moderate-to-severe plaque psoriasis
Market Sector
Dermatology
Development Status
Approved US and EU
